BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALN-PNP readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALN-PNP\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05648214-6782@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:ALN-PNP: Phase 1/2 readout est. (NCT05648214)
DESCRIPTION:ALN-PNP\, phase 1/2\, MASH / NASH.\nStudy: A Trial to Learn if 
 ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participant
 s With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)\nE
 stimated primary completion: 10 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/aln-pnp#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05648214
URL:https://assetmemo.bio/drug/aln-pnp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527910-6782@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:ALN-PNP: Phase 2 readout est. (NCT07527910)
DESCRIPTION:ALN-PNP\, phase 2\, MASH / NASH.\nStudy: A Phase 2a Study of AL
 N-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous P
 NPLA3-Related MASLD\nEstimated primary completion: 15 March 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/aln-pnp#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07527910
URL:https://assetmemo.bio/drug/aln-pnp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
